FDA Guidance for IRB Waiver or Alteration of Informed Consent

FDAGCP
Written by Brett Vengroff

The United States Food and Drug Administration (FDA) issued a guidance for immediate implementation to Sponsors, Investigators, and Institutional Review Boards for the waiver of alteration of informed consent for clinical investigations involving no more than minimal risk to human subjects.  Read the full guidance on FDA's website here.

Brett Vengroff
Previous

FDA releases final rule on Acceptance of Data from Clinical Investigations for Medical Devices
Next

Draft FDA Guidance on Electronic Records and Electronic Signatures in Clinical Investigations